Takashi Kojima

Kurume University — Japan

Medicine · Health Sciences

47h-index11.4kcitations358works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Esophageal Cancer Research and Treatment(183), Gastric Cancer Management and Outcomes(138), Cancer Immunotherapy and Biomarkers(94), Esophageal and GI Pathology(57), Lung Cancer Treatments and Mutations(50)

Publications357 total

Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients
JCO Oncology Practice·2025Open Access
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
ESMO Open·2025· 2 citedOpen Access
NEF2L2 rs35652124C>T Polymorphism Predicts Grade 4 Neutropenia in Esophageal Cancer Patients Treated with Docetaxel, Cisplatin, and Fluorouracil Chemotherapy: Results from Exploratory and Validation Cohorts
2025Open Access
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer
ESMO Open·2025· 5 citedOpen Access
Recent Trends and Patient Outcomes of Phase I Trials: A Single-Institution Experience in the Era of New Therapeutic Agents
JCO oncology advances.·2025Open Access
199. THE CORRELATION BETWEEN HISTOPATHOLOGICAL RESPONSE OF NIVOLUMAB-CONTAINING NEOADJUVANT CHEMOTHERAPY AND IMMUNE CELL TYPES FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Diseases of the Esophagus·2025Open Access
Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors
JCO Precision Oncology·2025· 1 citedOpen Access
155. INTER-INSTITUTIONAL SURVIVAL HETEROGENEITY BETWEEN SURGERY AND CHEMORADIOTHERAPY FOR CLINICAL STAGE I ESOPHAGEAL CANCER: EXPLORATORY ANALYSIS OF JCOG0502
Diseases of the Esophagus·2025Open Access
Clinical Significance of Extrachromosomal DNA in <i>FGFR2</i> -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience
JCO Precision Oncology·2025· 1 citedOpen Access
026. TECHNICAL DETAIL AND SHORT-TERM OUTCOMES OF ROBOT-ASSISTED CERVICAL MEDIASTINOSCOPIC ESOPHAGECTOMY (RACE)
Diseases of the Esophagus·2025Open Access
First-Line Docetaxel Once Every 2 Weeks With Cisplatin Plus Fluorouracil for Metastatic Esophageal Cancer: A Multicenter, Randomized Controlled Phase III Study (JCOG1314, MIRACLE)
JCO oncology advances.·2025Open Access
025. PERIOPERATIVE OUTCOMES IN ROBOT-ASSISTED ESOPHAGECTOMY AT OUR INSTITUTION: A COMPARATIVE PROPENSITY SCORE ANALYSIS OF 360 CASES VS. CONVENTIONAL VATS
Diseases of the Esophagus·2025
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer
ESMO Gastrointestinal Oncology·2025· 3 citedOpen Access
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
Annals of Surgery·2025· 3 citedOpen Access
Current status of prehabilitation before esophagectomy for patients with esophageal cancer among board-certified hospitals by the Japan Esophageal Society
Esophagus·2025· 2 cited
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306
Advances in Therapy·2025· 5 citedOpen Access
Supplementary Figure S8 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
2025Open Access
Table S1 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
2025Open Access
Supplementary Figure S2 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
2025Open Access
Supplementary Figure S5 from Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration
2025Open Access
page 1 of 18Next →

Frequent Co-authors

Toshihiko Doi(23), Ken Kato(23), Atsushi Ohtsu(12), Hiroki Hara(11), Akihito Kawazoe(11), Kohei Shitara(11), Yuko Kitagawa(11), Takayuki Yoshino(11), Yasutoshi Kuboki(10), Daisuke Kotani(9), Takahiro Tsushima(9), Yoshinori Ito(9), Hideaki Bando(9), Peter C. Enzinger(7), Takeshi Kuwata(7), Keiko Minashi(7), Hiroyuki Daiko(7), Yoshiaki Nakamura(7), Manish A. Shah(6), Antoine Adenis(6)